中国P站

Transplant immunology; Allorecognition; Immune tolerance; T-cell activation; Major histocompatibility complex; Direct allorecognition; Indirect allorecognition; Semi-direct pathway; Alloimmune response; Antigen-presenting cells; Regulatory T cells; Donor-specific tolerance; Immunological memory; Costimulatory signals; Rejection pathways.

Introduction

Transplantation immunology lies at the core of successful organ and tissue grafting. The ability of the recipient’s immune system to distinguish between self and non-self antigens is essential for protecting against pathogens, but it also presents a fundamental barrier to transplant acceptance. Immune recognition of donor antigens leads to rejection unless suppressed pharmacologically or managed immunologically. As a result, understanding the mechanisms underlying allorecognition and immune tolerance has become a cornerstone in transplant science. Advances in molecular immunology, cellular interactions, and antigen presentation pathways have deepened our knowledge of how the immune system reacts to foreign grafts—and how, in select cases, it can be trained to tolerate them. This exploration is crucial not only for minimizing rejection but also for designing long-lasting, immunosuppression-sparing therapies that improve graft survival and patient quality of life [1-5].

Description

At the heart of transplant immunology is the process of allorecognition, where the recipient's immune system identifies and responds to non-self major histocompatibility complex (MHC) molecules expressed by the donor tissue. This immune detection can occur via three primary pathways: direct, indirect, and semi-direct allorecognition. In direct allorecognition, recipient T cells recognize intact donor MHC molecules on donor antigen-presenting cells (APCs), leading to robust acute rejection responses. In indirect allorecognition, donor antigens are processed and presented by recipient APCs in the context of self-MHC, a pathway commonly associated with chronic rejection. The semi-direct pathway, a hybrid mechanism, involves the acquisition of intact donor MHC molecules by recipient APCs through mechanisms like trogocytosis or exosome transfer.

These mechanisms stimulate a cascade of immune events, beginning with T-cell activation. CD4+ helper T cells and CD8+ cytotoxic T cells, upon activation, proliferate and secrete cytokines such as IFN-γ and IL-2, promoting inflammation and direct cytotoxicity. Simultaneously, B-cell activation leads to the production of donor-specific antibodies (DSAs), contributing to antibody-mediated rejection. The activation and differentiation of these immune cells depend not only on antigen recognition but also on costimulatory signals provided by receptor-ligand interactions like CD28/B7 and CD40/CD40L. Blocking these pathways has become a therapeutic strategy in clinical transplantation to reduce immune activation [6-10].

Discussion

Despite the immune system's potent capacity to reject allografts, it also possesses regulatory mechanisms capable of fostering immune tolerance—a state in which the immune system becomes unresponsive or selectively responsive to donor antigens. Achieving this balance is the holy grail of transplantation. Key players in tolerance induction include regulatory T cells (Tregs), which suppress effector T cell responses and promote a tolerogenic environment through the release of anti-inflammatory cytokines such as IL-10 and TGF-β. Other components, including myeloid-derived suppressor cells and tolerogenic dendritic cells, also contribute to this immune regulation.

Strategies to induce tolerance have included mixed chimerism, where donor hematopoietic cells are engrafted into the recipient to promote central tolerance through thymic deletion, and co-stimulation blockade therapies that disrupt essential T-cell activation pathways. Moreover, tolerogenic vaccines, cell therapies, and gene editing techniques are being explored to modulate the immune response more precisely. Understanding the molecular signatures and immunological profiles associated with spontaneous or induced tolerance has become a major focus, particularly in liver and kidney transplant recipients who can sometimes maintain graft function after withdrawal of immunosuppression.

The delicate interplay between effector and regulatory immune responses also explains why immunosuppressive therapy must be carefully managed. While it prevents rejection, long-term immunosuppression suppresses beneficial immune regulation and increases the risk of infections and malignancy. Thus, current research is increasingly aimed at identifying biomarkers that can predict tolerance or impending rejection, allowing for personalized immunosuppression strategies.

Conclusion

Decoding the mechanisms of allorecognition and immune tolerance is critical for advancing transplant outcomes. A deeper understanding of how immune cells recognize, respond to, or tolerate donor antigens has led to innovative approaches that challenge the long-standing dependency on nonspecific immunosuppressants. Future directions include the use of immune-modifying biologics, cellular therapies like Tregs or tolerogenic APCs, and precision diagnostics to monitor immune status. Ultimately, integrating mechanistic immunology into clinical transplantation holds the potential to transform transplant medicine—turning it from a practice of immune suppression into one of immune orchestration. Achieving durable tolerance remains a formidable challenge, but with continued progress, it is an increasingly attainable goal.

References

1. Delgado JF, Reyne AG, de Dios S, López-Medrano F, Jurado A, et al. (2015) Influence of cytomegalovirus infection in the development of cardiac allograft vasculopathy after heart transplantation. J Heart Lung Transplant 3:1112-1119.

   Indexed at, Google Scholar, Crossref

2. Raffa GM, Di Gesaro G, Sciacca S, Tuzzolino F, Turrisi M, et al. (2016) Heart transplant program at IRCCS-ISMETT: Impact of mechanical circulatory support on pre- and post -transplant survival. Int J Cardiol 219: 358-361.

   Indexed at, Google Scholar, Crossref

3. Zieli艅ska K, Kukulski L, Wróbel M, Przyby艂owski P, Rokicka D, et al. (2022) Carbohydrate Metabolism Disorders in Relation to Cardiac Allograft Vasculopathy (CAV) Intensification in Heart Transplant Patients According to the Grading Scheme Developed by the International Society for Heart and Lung Transplantation (ISHLT). Ann Transplant 27: 933420.

   Indexed at, Google Scholar, Crossref

4. Conway J, Manlhiot C, Kirk R, Edwards LB, McCrindle BW, et al. Mortality and morbidity after retransplantation after primary heart transplant in childhood: an analysis from the registry of the International Society for Heart and Lung Transplantation. J Heart Lung Transplant 33: 241-251.

   Indexed at, Google Scholar, Crossref

5. R D Vanderlaan, C Manlhiot, L B Edwards, J Conway, B W McCrindle, et al. (2015) Risk factors for specific causes of death following pediatric heart transplant: An analysis of the registry of the International Society of Heart and Lung Transplantation. Pediatr Transplant 19: 896-905.

   Indexed at, Google Scholar, Crossref

6. Kitamura S (2012) Heart transplantation in Japan: a critical appraisal for the results and future prospects. Gen Thorac Cardiovasc Surg 60: 639-644.

   Indexed at, Google Scholar, Crossref

7. Wever-Pinzon O, Edwards LB, Taylor DO, Kfoury AG, Drakos SG, et al. (2017) Association of recipient age and causes of heart transplant mortality: Implications for personalization of post-transplant management-An analysis of the International Society for Heart and Lung Transplantation Registry. J Heart Lung Transplant 36: 407-417.

   Indexed at, Google Scholar, Crossref

8. Saczkowski R, Dacey C, Bernier PL (2010) Does ABO-incompatible and ABO-compatible neonatal heart transplant have equivalent survival. Interact Cardiovasc Thorac Surg 10: 1026-1033.

   Indexed at, Google Scholar, Crossref

9. Jeewa A, Manlhiot C, Kantor PF, Mital S, McCrindle BW, et al. (2014) Risk factors for mortality or delisting of patients from the pediatric heart transplant waiting list. J Thorac Cardiovasc Surg 147: 462-468.

   Indexed at, Google Scholar, Crossref

10. Sivathasan C, Lim CP, Kerk KL, Sim DK, Mehra MR, et al. (2017) Mechanical circulatory support and heart transplantation in the Asia Pacific region. J Heart Lung Transplant 36: 13-18.

    Indexed at, Google Scholar, Crossref